538 related articles for article (PubMed ID: 31906999)
1. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
2. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
Yagami A; Furue M; Togawa M; Saito A; Hide M
J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Hide M; Yagami A; Togawa M; Saito A; Furue M
Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics.
Hon KL; Li JTS; Leung AKC; Lee VWY
Expert Opin Pharmacother; 2021 Mar; 22(4):497-509. PubMed ID: 32990110
[TBL] [Abstract][Full Text] [Related]
5. Bilastine: a new H
Church MK; Labeaga L
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Refractoriness to an Up to Fourfold Dosage of Antihistamines in Isolated Chronic Spontaneous Urticaria.
Wongjirattikarn R; Chaowattanapanit S; Foocharoen C; Sawanyawisuth K; Choonhakarn C; Julanon N; Utchariyaprasit E
J Cutan Med Surg; 2022; 26(6):593-599. PubMed ID: 36172833
[TBL] [Abstract][Full Text] [Related]
7. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
8. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
Maurer M; Staubach P; Raap U; Richter-Huhn G; Bauer A; Ruëff F; Jakob T; Yazdi AS; Mahler V; Wagner N; Lippert U; Hillen U; Schwinn A; Pawlak M; Behnke N; Chaouche K; Chapman-Rothe N
Clin Exp Allergy; 2017 May; 47(5):684-692. PubMed ID: 28160338
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
[No Abstract] [Full Text] [Related]
12. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
Phinyo P; Koompawichit P; Nochaiwong S; Tovanabutra N; Chiewchanvit S; Chuamanochan M
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):956-970.e57. PubMed ID: 32916325
[TBL] [Abstract][Full Text] [Related]
14. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
[TBL] [Abstract][Full Text] [Related]
15. Cardiac safety of second-generation H
Cataldi M; Maurer M; Taglialatela M; Church MK
Clin Exp Allergy; 2019 Dec; 49(12):1615-1623. PubMed ID: 31519068
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
Church MK
Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine.
Curto-Barredo L; Giménez-Arnau AM
G Ital Dermatol Venereol; 2019 Aug; 154(4):444-456. PubMed ID: 30717573
[TBL] [Abstract][Full Text] [Related]
18. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.
Jáuregui I; García-Lirio E; Soriano AM; Gamboa PM; Antépara I
Expert Rev Clin Immunol; 2012 Jan; 8(1):33-41. PubMed ID: 22149338
[TBL] [Abstract][Full Text] [Related]
19. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria.
Krause K; Spohr A; Zuberbier T; Church MK; Maurer M
Allergy; 2013 Jul; 68(7):921-8. PubMed ID: 23742030
[TBL] [Abstract][Full Text] [Related]
20. Real-Life Experience of Efficacy and Safety of Bilastine in the Refractory Cases of Chronic Spontaneous Urticaria and its Effect on the Quality of Life of Patients.
De A; Godse K; Dhoot D; Sarda A
Indian J Dermatol; 2021; 66(2):159-164. PubMed ID: 34188271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
